Work

Therapeutic effects of a novel fusion of ALT-803, an IL-15 superagonist, with 4 single-chains of anti-CD20 antibody (2B8T2M) in combination with expanded natural killer cells against rituximab sensitive and resistant burkitt lymphoma (BL)

Year: 2018

Type: article

Source: Cytotherapy

DOI: 10.1016/j.jcyt.2018.02.295

Authors: Y. Chu, N. Su, S. Alter, E. Jeng, P. Rhode, M. Barth, D. Lee, H.C. Wong, M.S. Cairo

Institutions: New York Medical College, Altor BioScience (United States), University at Buffalo, State University of New York, Nationwide Children's Hospital

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4249235739

FWCI:

Cites:

Cited by:

Related to: 10